Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USFDA issues seven...

    USFDA issues seven observations on Sun Pharma Mohali site

    Written by supriya kashyap kashyap Published On 2016-11-25T11:23:03+05:30  |  Updated On 25 Nov 2016 11:23 AM IST

    Mumbai : The USFDA recorded seven observations as part of its recent inspection of Sun Pharma’s manufacturing site at Mohali. The site, which was earlier used to ship generic versions of popular cholesterol drug atorvastatin to the US, was brought under an import alert by the drug regulatory agency in Sept 2013.


    Sun Pharma BSE 0.64 % did not comment on the issue. The observations, addressed to Jila Breeze, Senior VP and head of global quality and compliance at Sun Pharma raised issues with the review process for the failure of a batch or any of its components in meeting specifications. In another observation, the FDA noted that laboratory records did not include complete data derived from all tests, examination and assay necessary to assure compliance with established specifications and standards.


    As its third observation, the US FDA officials represented by a team of three investigators, Steven Kehoe, Felix Maldonaldo and Daniel Roberts, said in the report that appropriate controls were not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.


    Referencing to a precision balance instrument, the FDA said there was no password protection and noted, "Laboratory analysts have the ability to change instrument settings including date and time on the instrument."


    "The quality control unit lacks authority to review production records to assure that no errors have occurred," the FDA added as part of its fifth observation related to good documentation practices in the quality systems. Another observation related to production system said no written procedures for production and process controls were designed to assure that the drug products have the identity, strength, quality and purity they purport or are represented to possess.


    Analysts told ET the FDA observations are not very serious in the initial reading but it depends on how these deviations are interpreted by the investigators. “Mohali was expected to be less complicated. It may be premature to conclude anything,” an expert advisor on manufacturing issues added.


    The Mohali site original belonged to Ranbaxy, a company that Sun Pharma acquired as part of a $4 billion deal completed last year. Ranbaxy’s manufacturing sites in India at Paonta Sahib, Dewas, Toansa and Mohali were put under an Import Alert as part of drawn-out investigations. In 2013, Ranbaxy BSE 5.63 % paid $500 million to settle the dispute with the US FDA.


    According to sources, the US FDA is presently carrying out a thorough investigation of Sun Pharma’s crucial site at Halol, Gujarat. Clearance of Halol site is crucial to Sun Pharma as the site contributed about 15% of Sun Pharma’s revenues in the US. For FY2016, Sun had combined sales of $4.3 billion of which the US alone contributed $2.1 billion.


    On BSE, Sun Pharma shares traded at Rs 688.45, down 1.8% around.

    cholesterol drugJila BreezeRanbaxySun PharmaUS Food & Drug AdministrationUSFDA
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok